Making safe sense of an anti-sense!

Gill, Upkar S.; Lemoine, Maud

doi:10.1016/j.xcrm.2021.100503

Cited by 1 publication

(2 citation statements)

References 10 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This stands in contrast to previous reports describing that in HBeAg‐positive NUC‐treated patients, ALT flares occur first and are then followed by HBsAg decline 59 . Currently, a phase II clinical trial aims to study the timing and mechanisms behind these ALT flares, by characterizing liver‐resident immune cells from patients treated with bepirovirsen (NCT04544956) 60 …”

Section: New Compounds Targeting Hbv As An Indirect Approach Against Hdvmentioning

confidence: 84%

“…59 Currently, a phase II clinical trial aims to study the timing and mechanisms behind these ALT flares, by characterizing liver-resident immune cells from patients treated with bepirovirsen (NCT04544956). 60 The second molecule in this category is RO7062931, a GalNAcconjugated locked nucleic acid (LNA)-containing ASO, which has recently completed a phase I clinical trial to evaluate its safety and potential antiviral effect (NCT03038113). This study reported RO7062931 to be safe and well tolerated after 4 weeks of treatment.…”

Section: Targeting Hbv Gene Expressionmentioning

confidence: 99%

See 1 more Smart Citation

Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity

Suarez

Batbold²,

Bartosch

et al. 2023

Liver International

View full text Add to dashboard Cite

Hepatitis delta virus (HDV) is a satellite RNA virus that requires the presence of hepatitis B virus (HBV) for its replication. HDV/HBV co‐infection is often associated with a faster disease progression of chronic hepatitis in comparison to HBV mono‐infection. Therefore, the development of novel antiviral therapies targeting HDV represents a high priority and an urgent medical need. In this review, we summarize the ongoing efforts to evaluate promising HDV‐specific drugs, such as lonafarnib (LNF), pegylated interferon lambda (PEG‐IFN‐λ) and their use as a combination therapy. Furthermore, we review the most recent developments in the area of anti‐HBV drugs with potential effects against HDV, including therapeutic agents targeting hepatitis B surface antigen (HBsAg) expression, secretion and function. Finally, we consider the important insights that have emerged from the development of these potential antiviral strategies, as well as the intriguing questions that remain to be elucidated in this rapidly changing field.

show abstract

Section: New Compounds Targeting Hbv As An Indirect Approach Against Hdvmentioning

confidence: 84%

Section: Targeting Hbv Gene Expressionmentioning

confidence: 99%